Human Insulin Drug Market, By Application (Type I Diabetes and Type II Diabetes), By Product Type (Human Insulin Drugs and Human Insulin Delivery Devices), By Delivery Devices (Syringes, Pens, and Pen Needles), By Drug (Insulin Analogs & Biosimilar, and Human Insulin Biologics), By Region Analysis - Global Analysis And Industry Forecast Report Till 2030.

The Global Human Insulin Drug Market is projected to grow from $44.35 billion to $73.22 billion, at a CAGR of 7.8% in terms of revenue during the forecast period 2021-2030.

The body's blood sugar levels are regulated by the hormone insulin. Diabetes is a long-term medical disease in which a person has high blood sugar or glucose levels. Currently, there are two main kinds of diabetes. In type 1 diabetes, the beta cells of the pancreas cease producing insulin, whereas, in type 2, the body's cells become less sensitive to the insulin that is produced.

The adoption of human insulin will be firmly supported by the increasing incidence of diabetes globally, which will support market expansion. The insulin market is expected to grow as a result of the rising incidence of diabetes caused by an increase in sedentary lifestyle adoption. Additionally, it is predicted that favorable reimbursement practices in industrialized nations will expand the market.

Market Dynamics:

Drivers:

The main causes of the rise in diabetes around the world are obesity and an inactive lifestyle. In the recent decades, the prevalence of diabetes has increased considerably, and it is predicted that this trend will continue in the decades to come.

The prevalence of type 1 diabetes is high. Insulin is required for daily glycemic management in persons with type 1 diabetes. More than 9.0 million people worldwide are believed to have type-1 diabetes, according to a study that was published in Diabetologia.

Restraints:

Due to the adoption of new products and ongoing developments, the demand for insulin has significantly increased over the past ten years. However, the lack of reimbursement in developing and emerging nations limited the market's expansion to some degree. Additionally, a greater prevalence of undiagnosed diabetes cases in developing nations hinders the market's overall growth.

Opportunities:

Numerous novel products are being introduced in the insulin market all over the world. To increase their market share and fuel the rise of the human insulin market, manufacturers are concentrating on creating novel insulin products. For instance, in May 2022, Eli Lilly and Company was granted clearance for their Mounjaro injection, which helps patients with type 2 diabetes improve their glycemic control. These are a few of the elements encouraging the market's expansion and offering excellent chances.

Key Players:

• Novo Nordisk A/S

• Eli Lilly and Company

• Sanofi

• Biocon Ltd

• Wockhardt

• Boehringer Ingelheim International GmbH

• Julphar

• United Laboratories International Holdings Limited

• Tonghua Dongbao Pharmaceutical Co. Ltd.

• Adocia

• Merck & Co., Inc.

• Pfizer, Inc.

• Bristol-Myers Squibb Company.

• GlaxoSmithKline Plc.

• Oramed Pharmaceuticals, Inc.

Market Segmentation:

Human Insulin Drug Market, By Drug

• Insulin Analogs and Biosimilar

• Human Insulin Biologics

Human Insulin Drug Market, By Application

• Type I Diabetes

• Type II Diabetes

 Human Insulin Drug Market, By Product

• Human Insulin Drugs

• Human Insulin Delivery Devices

 Human Insulin Drug Market, By Delivery Devices

• Syringes

• Pens

• Pen needles

 Human Insulin Drug Market, By Region Type

• North America 

• Europe 

• Asia-Pacific 

• LAMEA 

Regional Analysis:

In 2021, North America brought in USD XX billion. The insulin drug market in North America is being driven by several factors, including the significant presence of the main insulin manufacturers, fierce competition among businesses, and the rising prevalence of type 1 diabetes. For instance, the American Diabetes Association (ADA) estimates that approximately 187,000 children and teenagers and XX million adults in the United States have type-1 diabetes. In addition, the rising cost of insulin in the United States over the past ten years has allowed the North American market to capture a sizable part of the global market.

Growing geriatric and target populations, an increase in collaborations for the development of geographic expansion of key players, biosimilars and active participation of the government and nonprofit sectors in the market space are all contributing factors that will cause Asia Pacific to experience significant growth over the forecast period. Additionally, regional market expansion may be aided by health awareness initiatives and scientific conferences for the management of this disease.

Scope of the report:

User

Tab Content